Taiwan Advance Bio-Pharmaceutical Inc.
Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China, Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA, rapid, and chemical test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and… Read more
Taiwan Advance Bio-Pharmaceutical Inc. (4186) - Net Assets
Latest net assets as of June 2025: NT$252.55 Million TWD
Based on the latest financial reports, Taiwan Advance Bio-Pharmaceutical Inc. (4186) has net assets worth NT$252.55 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$692.33 Million) and total liabilities (NT$439.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$252.55 Million |
| % of Total Assets | 36.48% |
| Annual Growth Rate | -17.09% |
| 5-Year Change | -28.55% |
| 10-Year Change | N/A |
| Growth Volatility | 21.02 |
Taiwan Advance Bio-Pharmaceutical Inc. - Net Assets Trend (2019–2024)
This chart illustrates how Taiwan Advance Bio-Pharmaceutical Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Taiwan Advance Bio-Pharmaceutical Inc. (2019–2024)
The table below shows the annual net assets of Taiwan Advance Bio-Pharmaceutical Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$256.44 Million | +9.63% |
| 2023-12-31 | NT$233.92 Million | -4.38% |
| 2022-12-31 | NT$244.64 Million | +1.32% |
| 2021-12-31 | NT$241.45 Million | -32.72% |
| 2020-12-31 | NT$358.90 Million | -45.19% |
| 2019-12-31 | NT$654.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Taiwan Advance Bio-Pharmaceutical Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6228900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$900.00 Million | 350.96% |
| Other Comprehensive Income | NT$-1.05 Million | -0.41% |
| Total Equity | NT$256.44 Million | 100.00% |
Taiwan Advance Bio-Pharmaceutical Inc. Competitors by Market Cap
The table below lists competitors of Taiwan Advance Bio-Pharmaceutical Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zelluna ASA
OL:ZLNA
|
$19.59 Million |
|
Ege Seramik Sanayi ve Ticaret AS
IS:EGSER
|
$19.60 Million |
|
Tamawood Ltd
AU:TWD
|
$19.60 Million |
|
Fleming Properties AB
ST:FLMNG
|
$19.60 Million |
|
Samchuly Bicycle Co. Ltd
KQ:024950
|
$19.59 Million |
|
ZINNWALD LITHIUM LS -01
F:7WW
|
$19.59 Million |
|
TOUBF
PINK:TOUBF
|
$19.57 Million |
|
Welltend Technology Corp
TW:3021
|
$19.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Taiwan Advance Bio-Pharmaceutical Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 233,920,000 to 256,441,000, a change of 22,521,000 (9.6%).
- Net income of 22,875,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 694,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$22.88 Million | +8.92% |
| Other Comprehensive Income | NT$-694.00K | -0.27% |
| Other Changes | NT$340.00K | +0.13% |
| Total Change | NT$- | 9.63% |
Book Value vs Market Value Analysis
This analysis compares Taiwan Advance Bio-Pharmaceutical Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.06x to 3.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$2.58 | NT$10.45 | x |
| 2020-12-31 | NT$4.43 | NT$10.45 | x |
| 2021-12-31 | NT$2.68 | NT$10.45 | x |
| 2022-12-31 | NT$2.72 | NT$10.45 | x |
| 2023-12-31 | NT$2.60 | NT$10.45 | x |
| 2024-12-31 | NT$2.85 | NT$10.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Taiwan Advance Bio-Pharmaceutical Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.92%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.46%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 2.64x
- Recent ROE (8.92%) is above the historical average (-26.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -89.48% | -84.87% | 0.31x | 3.36x | NT$-194.19 Million |
| 2020 | -24.07% | -36.67% | 0.29x | 2.29x | NT$-122.28 Million |
| 2021 | -49.09% | -48.70% | 0.34x | 2.96x | NT$-142.67 Million |
| 2022 | 1.30% | 1.00% | 0.45x | 2.89x | NT$-21.29 Million |
| 2023 | -4.57% | -3.38% | 0.42x | 3.20x | NT$-34.07 Million |
| 2024 | 8.92% | 6.46% | 0.52x | 2.64x | NT$-2.77 Million |
Industry Comparison
This section compares Taiwan Advance Bio-Pharmaceutical Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Taiwan Advance Bio-Pharmaceutical Inc. (4186) | NT$252.55 Million | -89.48% | 1.74x | $19.59 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |